Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 2.75% | 37.87% | -0.21% | 80.44% | 0.47% |
| Total Depreciation and Amortization | -2.51% | -1.24% | 0.41% | 0.84% | -0.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -2.75% | -83.68% | 0.27% | -62.43% | -0.50% |
| Change in Net Operating Assets | 2.74% | 56.34% | -0.21% | -186.60% | 0.48% |
| Cash from Operations | 2.75% | 43.99% | -0.21% | 70.49% | 0.47% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -2.58% | 201.97% | 0.00% | -200.66% | 0.00% |
| Cash from Investing | -2.58% | 201.97% | 0.00% | -200.66% | 0.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | -13.73% | 0.00% | 0.78% | 0.00% |
| Issuance of Common Stock | 0.00% | -- | -- | -100.00% | 0.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -1,006.43% | 0.00% | 95.77% | 0.00% |
| Cash from Financing | -2.75% | 12,333.57% | -0.24% | -100.45% | -0.47% |
| Foreign Exchange rate Adjustments | -4.44% | 102.14% | -0.24% | -494.60% | 0.28% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2.75% | 144.97% | -0.20% | 30.33% | 0.47% |